NCT01651481

Study to Evaluate the Pharmacokinetics and Safety of Singulair and Xyzal in Free Combination and Fixed-dose Combination

Open-label, Randomized, Single Dose Crossover Study to Evaluate the Pharmacokinetics and Safety of Singulair (10 mg) and Xyzal (5 mg) in Free Combination and Fixed-dose Combination as HCP1102 in Healthy Male Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: Male
• Age: 20 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of Singulair (10 mg) and Xyzal (5 mg) in free combination and fixed-dose combination as HCP1102

Conditions

• Rhinitis

Interventions

Type	Name	Description
DRUG	HCP1102
DRUG	Singulair and Xyzal

Timeline

• Start date: 2012-07-01
• Primary completion: 2012-09-01
• Completion: 2012-12-01
• First posted: 2012-07-27
• Last updated: 2013-08-13

Locations

1 site across 1 country: South Korea